83
Participants
Start Date
September 10, 2014
Primary Completion Date
February 27, 2019
Study Completion Date
February 27, 2019
INCB052793
Initial cohort dose of INCB052793 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria.
gemcitabine
Gemcitabine administered intravenously over 30 minutes at the protocol-specified dose and frequency.
nab-paclitaxel
nab-paclitaxel administered intravenously over 30 minutes at the protocol-specified dose and frequency.
dexamethasone
Dexamethasone administered orally at the protocol-specified dose and frequency.
Carfilzomib
Carfilzomib administered intravenously at the protocol-specified dose and frequency.
bortezomib
Bortezomib administered intravenously or subcutaneously at the protocol-specified dose and frequency.
lenalidomide
Lenalidomide administered orally at the protocol-specified dose and frequency.
azacitidine
Azacitidine administered subcutaneously at the protocol-specified dose and frequency.
INCB052793
INCB052793 tablets administered orally at the protocol specified dose strength and frequency.
pomalidomide
Pomalidomide administered orally at the protocol-specified dose and frequency.
INCB050465
INCB050465 tablets administered orally at the protocol specified dose strength and frequency.
INCB039110
INCB039110 tablets administered orally at the protocol specified dose strength and frequency.
Birmingham
West Hollywood
New Haven
Atlanta
Chicago
Indianapolis
Hackensack
New York
Durham
Portland
Greenville
Site 2, Nashville
Nashville
Dallas
Lead Sponsor
Incyte Corporation
INDUSTRY